Under the deal, the Livongo for Diabetes program will be offered with Voluntis’ Insulia, an FDA-cleared medical device and app that provides basal insulin dose recommendations for people with Type 2 diabetes. The two companies will create an expanded solution that aims to improve medication adherence and optimization by offering better information personalized to Livongo members.